960305-54-8

Basic information

• Product Name: 2-tert-Butyl 7-methyl 3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate
• Synonyms: 2-tert-Butyl 7-methyl 3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate;3,4-Dihydro-1H-isoquinoline-2,7-dicarboxylic acid 2-tert-butyl ester 7-methyl ester;2-tert-butyl 7-methyl 1,2,3,4-tetrahydroisoquinoline-2,7-dicarboxylate;Methyl 2-Boc-1,2,3,4-tetrahydro-isoquinoline-7-carboxylate
• CAS NO: 960305-54-8
• Molecular Formula: C16H21NO4
• Molecular Weight: 291.35
• Mol File: 960305-54-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-tert-Butyl 7-methyl 3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-tert-Butyl 7-methyl 3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate(960305-54-8)
• EPA Substance Registry System: 2-tert-Butyl 7-methyl 3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate(960305-54-8)

Safety Data

• Hazardous Substances Data: 960305-54-8(Hazardous Substances Data)

Usage

General Description

2-tert-Butyl 7-methyl 3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate is a chemical compound that contains a dihydroisoquinoline core structure with two carboxylate functional groups. It is a derivative of isoquinoline, which has been shown to exhibit various pharmacological properties such as anti-inflammatory, analgesic, and antioxidant effects. The presence of the tert-butyl and methyl substituents in this compound may influence its pharmacokinetic and pharmacodynamic properties. Research on this chemical is ongoing to explore its potential applications in drug development and medical treatment.

Upstream product

• 67-56-1 methanol 
• 258515-65-0 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester 
• 201230-82-2 carbon monoxide 
• 149353-95-7 2-[(tert-butoxy)carbonyl]-1 ,2,3,4-tetrahydroisoquinoline-7-carboxylic acid 
• 75-52-5 nitromethane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 220247-69-8 methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate hydrochloride 

Downstream Products

• 149353-95-7 2-[(tert-butoxy)carbonyl]-1 ,2,3,4-tetrahydroisoquinoline-7-carboxylic acid 
• 1436423-83-4 2-butyryl-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 
• 1436422-20-6 2-butyl-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 
• 1436422-17-1 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 
• 1436426-34-4 tert-butyl 7-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1436422-07-9 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-(2-(methylsulfonyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 
• 220247-50-7 methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate 

Relevant articles and documents

INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT

The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R1, R2, R3, R4, R6

MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion.

Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds

Compounds of a certain formula I wherein R1, R2, R3, X, Y, r, s, t, u and v have the meanings as defined in the specification, and the salts, solvates and hydrates thereof are novel effective HDAC 6 inhibitors.